1. Home
  2. GANX vs NRT Comparison

GANX vs NRT Comparison

Compare GANX & NRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GANX
  • NRT
  • Stock Information
  • Founded
  • GANX 2017
  • NRT 1975
  • Country
  • GANX United States
  • NRT United States
  • Employees
  • GANX N/A
  • NRT N/A
  • Industry
  • GANX Biotechnology: Pharmaceutical Preparations
  • NRT Oil & Gas Production
  • Sector
  • GANX Health Care
  • NRT Energy
  • Exchange
  • GANX Nasdaq
  • NRT Nasdaq
  • Market Cap
  • GANX 53.8M
  • NRT 44.0M
  • IPO Year
  • GANX 2021
  • NRT N/A
  • Fundamental
  • Price
  • GANX $1.77
  • NRT $5.18
  • Analyst Decision
  • GANX Strong Buy
  • NRT
  • Analyst Count
  • GANX 5
  • NRT 0
  • Target Price
  • GANX $8.20
  • NRT N/A
  • AVG Volume (30 Days)
  • GANX 247.1K
  • NRT 37.1K
  • Earning Date
  • GANX 08-07-2025
  • NRT 05-30-2025
  • Dividend Yield
  • GANX N/A
  • NRT 9.07%
  • EPS Growth
  • GANX N/A
  • NRT 24.05
  • EPS
  • GANX N/A
  • NRT 0.59
  • Revenue
  • GANX N/A
  • NRT $6,184,173.00
  • Revenue This Year
  • GANX N/A
  • NRT N/A
  • Revenue Next Year
  • GANX N/A
  • NRT N/A
  • P/E Ratio
  • GANX N/A
  • NRT $8.83
  • Revenue Growth
  • GANX N/A
  • NRT 18.55
  • 52 Week Low
  • GANX $0.89
  • NRT $3.88
  • 52 Week High
  • GANX $3.19
  • NRT $6.90
  • Technical
  • Relative Strength Index (RSI)
  • GANX 44.69
  • NRT 57.49
  • Support Level
  • GANX $1.85
  • NRT $5.05
  • Resistance Level
  • GANX $1.81
  • NRT $5.45
  • Average True Range (ATR)
  • GANX 0.15
  • NRT 0.20
  • MACD
  • GANX -0.01
  • NRT -0.01
  • Stochastic Oscillator
  • GANX 32.61
  • NRT 52.24

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.

About NRT North European Oil Royality Trust

North European Oil Royalty Trust holds overriding royalty rights covering gas and oil production in certain concessions or leases in the Federal Republic of Germany. The properties of the trust are overriding royalty rights on sales of gas, sulfur, and oil under certain concessions or leases in the Federal Republic of Germany. The trust also holds other royalty rights, which are based on leases. It receives various percentages of royalties on the proceeds of the sales of certain products from the areas involved.

Share on Social Networks: